Lower colon cancer risk with GLP-1 RAs compared with other diabetes drugs: study
![](https://www.ausdoc.com.au/wp-content/uploads/2023/12/4x3_colon_dreamstime_m_118445175-1-300x225.jpg)
Patients using GLP-1 receptor agonists for type 2 diabetes have lower odds of colorectal cancer than those who take other medications such as metformin, insulin and SGLT-2 inhibitors, a US study shows.
“To our knowledge, this is the first indication this popular weight-loss and anti-diabetic class of drugs reduces incidence of colorectal cancer, relative to other anti-diabetic agents,” said co-lead author Dr Rong Xu (PhD) from Case Western Reserve University in Cleveland, Ohio.